CTLA4 and melanoma: Following the success of this clinical trial, two recent clinical trials have set out to investigate C-REV as a combination therapy with a CTLA-4 inhibitor, ipilimumab (NCT03153085), in Japanese patients with unresectable or metastatic melanoma or with a PD-1 inhibitor, nivolumab (NCT03259425), in patients with resectable stage IIIB, IIIC, or IVM1a melanoma.